The share price of Kite Pharma (Nasdaq: KITE) shot up by more than 9% on Tuesday after the US oncology biopharma specialist announced positive top-line data in a trial of its KTE-C19 candidate in non-Hodgkin lymphoma (NHL).
In a pre-planned interim analysis of the ZUMA-1 trial, KTE-C19, which is the company’s lead product candidate, met the primary endpoint of objective response rate (ORR).
ZUMA-1 enrolled patients with chemo-refractory aggressive NHL into two cohorts. Cohort 1 included patients with chemo-refractory diffuse large B-cell lymphoma (DLBCL).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze